Combination Drug Shows Efficacy in Tough-to-Treat Blood Cancer - PharmaLive

 
 
Combination Drug Shows Efficacy in Tough-to-Treat Blood CancerPharmaLiveWritten by: BioSpace | news@biospace.com | Dated: Friday, August 23rd, 2019. Published: Aug. 23, 2019. By Alex Keown. Multiple Myeloma. Researchers may ...
 
Related NewsFeeds

Oncolytics Biotech(R) Receives Nasdaq Notification LetterYahoo FinanceSAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / September 20, 2019 / Oncolytics BiotechAE Inc. (ONCY) (ONC.TO), currently developin

7 visits

Blast Off With Rocket PharmaceuticalsSeeking AlphaRCKT has solid pipeline assets and plenty of catalysts during next 12 months for value creation. There are no near-term funding needs. The pipeline

2 visits

Indianapolis funding news: Biotech company tops recent local investmentsHoodlineIndianapolis-based biotechnology company Scioto Biosciences has secured $2.3 million in grant funding. Read on for the

8 visits

Pharmaceuticals: Due to carcinogenic impurities found in Ranitidine, there could be disruptions in supply of productThe Financial ExpressDRRD re-launched isotretinoin caps recently. The market share

8 visits

Playing with diabetes, Luke Kunin has kept on skating all the way to the NHLThe AthleticDiagnosed at 12, the now-Wild forward continues to manage the condition while playing at the highest level of

8 visits

Adipose Tissue-derived Stem Cells Market Size Set for Rapid Growth and Trend by2018 - 2028My Health ReporterAdipose tissue is rich in multi potent stem cells that have the capability to differentiat

0 visits

First Ever Drug/Bio Combo IND Approved by FDA for Lumbar Fusionhttps://ryortho.com/The FDA just approved the first ever Investigational New Drug (IND) application to evaluate a drug/biologic combina

0 visits

Grosse Pointe Park girl writes book to raise awareness for type 1 diabetesWDIV ClickOnDetroitNorah Brumbaugh, of Grosse Pointe Park, was just 7-years-old when she was diagnosed with type 1 diabetes.

0 visits

Delisting of Securities of Hunter Maritime Acquisition Corp., ADOMANI, Inc., Xynomic Pharmaceuticals Holdings, Inc., China TechFaith Wireless Communication Technology Limited, and Warrant of Allied Es

0 visits

Go-Private Offer For China Biologic Products: It Is UndervaluedSeeking AlphaAs of September 18, 2019, the company received a non-binding proposal to be acquired for $120/share. Joseph Chow, the CEO,

0 visits

Lupus Nephritis Market Recent Industry Trends and DevelopmentsCommerce GazetteGlobal Lupus Nephritis Market. Lupus nephritis refers to the kidney damage caused by the disease lupus erythematosus. Lu

0 visits

Molecular Diagnostics Market: Worldwide Prospects, Share, Crucial Players, Size, Competitive Breakdown and Regional Forecast 2015 - 2021NewsVarsityIn-vitro diagnostics is a method of performing a di

0 visits

Infection Rates Similar With TNFi Plus Methotrexate, Triple TherapyRheumatology AdvisorResearchers found data that showed that patients with rheumatoid arthritis who are treated with a tumor necrosi

0 visits

Lawmakers Join Diabetes Advocates, Patients, for Press Conference Monday About Reducing Insulin CostsRiverBender.comSPRINGFIELD State lawmakers will join diabetes advocates and patients directly imp

0 visits

Study Finds Minorities More Likely to Have Diabetes at Lower WeightsdLife.comMembers of racial and ethnic minority groups are much more likely to have diabetes or prediabetes at lower weights - even

0 visits

Diabetes Risk Is Related to Hormones in WomenEveryday HealthNew research suggests that women who take birth control pills are at a higher risk for developing type 2 diabetes (T2D), even after contro

0 visits

French weight-loss pill scandal set for landmark trialPharmaLiveWritten by: Reuters Health | no-reply@reuters.com | Dated: Friday, September 20th, 2019. PARIS (Reuters) - A landmark French trial wil

10 visits

Allogene Partnering with Stanford to Develop Better CAR-T TherapiesPharmaLivePublished: Sep 20, 2019 By Mark Terry. CAR-T. South San Francisco-based Allogene Therapeutics inked a research collaborat

10 visits

Allogene, Stanford to Develop Better CAR-T TherapiesPharmaLivePublished: Sept. 20, 2019. By Mark Terry. CAR-T. South San Francisco-based Allogene Therapeutics inked a research collaboration deal wit

0 visits

Top Infectious Disease News of the Week-September 15, 2019Contagionlive.comStay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

0 visits